Getty Images In a study, a positive PSMA PET/CT scan was associated with a significant 4.5-fold higher adjusted risk for disease progression. Positive results on PSMA PET/CT scans predict more ...

Getty Images Ga 68 PSMA-11 PET can detect sites of local recurrence or metastasis in patients with biochemical evidence of recurrent prostate cancer. The FDA has approved gallium 68 PSMA-11 (Ga 68 ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Reston, VA—In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy. Published in the July issue of The ...

PSMA PET-CT is a diagnosit tool helping save men's lives with prostate cancer that has spread beyond the prostate gland Dr. David Samadi says that men with aggressive prostate cancer or a very high ...

Changes in planned disease management after piflufolastat F18 PET/CT in men with biochemically recurrent prostate cancer and low PSA levels: A secondary analysis of results from the CONDOR study. This ...

Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) ...

Gozellix, a PSMA-PET imaging agent, is FDA-approved for detecting prostate cancer metastasis and recurrence, enhancing access to advanced imaging. The approval is supported by data from the PSMA-PreRP ...

Advanced imaging techniques are allowing clinicians to pinpoint exactly where prostate cancer has spread in the body, therefore lending the opportunity for more exact staging and targeted treatment ...

Please provide your email address to receive an email when new articles are posted on . A novel molecular imaging technique demonstrated higher diagnostic accuracy than conventional imaging among a ...

The FDA today approved Gallium 68 PSMA-11 as the first drug for PET imaging of prostate-specific membrane antigen-positive lesions in men with prostate cancer, according a press release from the ...